These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 29793946)

  • 1. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
    Dickler MN; Saura C; Richards DA; Krop IE; Cervantes A; Bedard PL; Patel MR; Pusztai L; Oliveira M; Cardenas AK; Cui N; Wilson TR; Stout TJ; Wei MC; Hsu JY; Baselga J
    Clin Cancer Res; 2018 Sep; 24(18):4380-4387. PubMed ID: 29793946
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
    Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
    Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
    Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
    Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
    Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpelisib for
    André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
    N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
    Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in
    Pascual J; Lim JSJ; Macpherson IR; Armstrong AC; Ring A; Okines AFC; Cutts RJ; Herrera-Abreu MT; Garcia-Murillas I; Pearson A; Hrebien S; Gevensleben H; Proszek PZ; Hubank M; Hills M; King J; Parmar M; Prout T; Finneran L; Malia J; Swales KE; Ruddle R; Raynaud FI; Turner A; Hall E; Yap TA; Lopez JS; Turner NC
    Cancer Discov; 2021 Jan; 11(1):92-107. PubMed ID: 32958578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
    Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Juric D; Krop I; Ramanathan RK; Wilson TR; Ware JA; Sanabria Bohorquez SM; Savage HM; Sampath D; Salphati L; Lin RS; Jin H; Parmar H; Hsu JY; Von Hoff DD; Baselga J
    Cancer Discov; 2017 Jul; 7(7):704-715. PubMed ID: 28331003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
    Grinshpun A; Ren S; Graham N; DeMeo MK; Wrabel E; Carter J; Tayob N; Pereslete A; Hamilton E; Juric D; Mayer EL; Tolaney SM; Krop IE; Metzger O
    ESMO Open; 2024 Jun; 9(6):103465. PubMed ID: 38833970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
    André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
    Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
    Baird RD; van Rossum AGJ; Oliveira M; Beelen K; Gao M; Schrier M; Mandjes IAM; Garcia-Corbacho J; Vallier AL; Dougall G; van Werkhoven E; Linossi C; Kumar S; van Tinteren H; Callari M; Beddowes E; Perez-Garcia JM; Rosing H; Platte E; Nederlof P; Schot M; de Vries Schultink A; Bernards R; Saura C; Gallagher W; Cortès J; Caldas C; Linn SC
    Clin Cancer Res; 2019 Nov; 25(22):6598-6605. PubMed ID: 31439579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
    Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Vuylsteke P; Huizing M; Petrakova K; Roylance R; Laing R; Chan S; Abell F; Gendreau S; Rooney I; Apt D; Zhou J; Singel S; Fehrenbacher L
    Ann Oncol; 2016 Nov; 27(11):2059-2066. PubMed ID: 27573562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
    Tolaney SM; Toi M; Neven P; Sohn J; Grischke EM; Llombart-Cussac A; Soliman H; Wang H; Wijayawardana S; Jansen VM; Litchfield LM; Sledge GW
    Clin Cancer Res; 2022 Apr; 28(8):1500-1506. PubMed ID: 35121623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
    Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
    Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.